Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
2-methyl-3,5,7,8-tetrahydro-4H-thiopyrano[4,3-d]pyrimidin-4-one is a synthetic small molecule belonging to the pyranopyrimidine class. It is primarily known as an experimental compound and has not been approved for clinical use. The compound acts as an inhibitor of poly [ADP-ribose] polymerase 1 (PARP1) and protein mono-ADP-ribosyltransferase PARP3 (PARP3), with reported binding affinities in the nanomolar to micromolar range. These enzymes are involved in DNA repair processes; thus PARP inhibitors are of interest for potential anticancer applications by exploiting synthetic lethality in tumor cells deficient in DNA repair pathways. There are no known approved indications or marketed products containing this molecule[1][6].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on 2-methyl-3,5,7,8-tetrahydro-4H-thiopyrano[4,3-d]pyrimidin-4-one.